StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$7.10+0.26 (+3.80%)

Close on Nov 18, 2026Market cap $27.18MP/E –Yield –

Pelthos Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Pelthos Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $43.30M. For fiscal 2025 it was $16.80M.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.80M–
FY2024Dec 31, 2024$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$15.60M–
Q1 FY2026Mar 31, 2026$10.91M–
Q4 FY2025Dec 31, 2025$9.39M–
Q3 FY2025Sep 30, 2025$7.41M–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$0–

More Pelthos Therapeutics figures

See a number that looks wrong?